CClinicalTrials.gg
CompletedNCT00143845Updated Mar 8, 2017Results posted

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

A Phase 2 interventional study of Reduced intensity conditioning and Rapid immunosuppressive taper in Multiple Myeloma, Lymphocytic Leukemia, Chronic and Lymphoma, Low-Grade, sponsored by University of Michigan Rogel Cancer Center. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2017-03-08.

Sponsored by University of Michigan Rogel Cancer Center · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Sex
All
01

Study summary

The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.

Read the detailed description

In this research study patients will receive dosages of chemotherapy that are lower than the usual dosages. The study will determine whether a shorter duration of immunosuppression will permit the donor cells to be effective against the cancer without causing more severe GVHD (Graft Versus Host Disease). Also to be determined is whether the patient's cancer can be prevented from relapsing after blood stem cell transplant by using prophylactic treatment, giving a donor leukocyte infusion BEFORE a relapse happens.

In this research study samples of blood and bone marrow will be analyzed. These samples will be examined to study the cellular production of inflammatory cytokine levels in attempt to be able to predict which patients will have complications like GVHD or relapse.

02

Conditions studied

  • Multiple Myeloma
  • Lymphocytic Leukemia, Chronic
  • Lymphoma, Low-Grade
03

In context

Multiple Myeloma

3,632 studies on the registry are indexed under Multiple Myeloma; 745 are open to participants now.

This study's enrollment of 54 is above the median of 41 across 2,907 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

University of Michigan Rogel Cancer Center is the lead sponsor of 316 studies on the registry; 46 are open to participants now.

Of its 46 completed or terminated interventional studies of FDA-regulated products, 30 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patient Inclusion Criteria:

To be eligible a patient MUST meet at least one of the next 4 criteria

  • Any patient aged 55 years or older with a hematological malignancy for which allogeneic transplant is considered an appropriate treatment, AND/OR
  • Any patient, regardless of age, with a hematologic malignancy for which allogeneic transplant is considered an appropriate treatment and the patient is not eligible for a conventional myeloablative transplant because of organ dysfunction AND/OR
  • Any patient, regardless of age, who has relapsed following prior autologous or allogeneic transplant for a hematologic malignancy AND/OR
  • Any patient, regardless of age, with one of the following hematological malignancies:

    1. Multiple myeloma

      1. refractory to or failure following conventional chemotherapy such as VAD (Vincristine, Adriamycin and Dexamethasone), pulse decadron, or alkylating agents, or
      2. chromosomal abnormality associated with poor prognosis by cytogenetics or FISH probe.
    2. Chronic lymphocytic leukemia patients, Rai stage 3 or 4 and relapsed following/refractory to alkylating agents or nucleoside analog therapy
    3. Low grade lymphoma (small lymphocytic, follicular small cleaved cell, or follicular mixed small cleaved and large cell) that is either relapsed or refractory provided the disease is NOT rapidly progressive, NOT bulky, and no mass exceeds 5 cm in greatest dimension.

To be eligible a patient MUST meet all of the following criteria

  • In addition to the above criteria ALL patients must meet the following minimum organ function:

    1. Cardiac: Ejection fraction at least 30%.
    2. Renal: Adequate renal function as defined by creatinine \< 2.0mg OR creatinine clearance >40 mg/min by 24-hour urine collection or GFR (Glomerular Filtration Rate. (Gender and age-adjusted creatinine clearance >40ml/min by Gault-Cockroft 55 is acceptable for adults: (140 - age) x weight/72 x Scr [x 0.85 if female]).
    3. Pulmonary: FEV1 and FVC >60%.
    4. Hepatic: Total bilirubin \<2.0 and AST (Aspartate Aminotransferase)/ALT (Alanine Transaminase) \< 3X institutional normal for age.
    5. Performance (adults): Karnofsky score must be at least 60; for pts. under 16, Lansky score must be at least 60.
  • Availability of a 5/6 or 6/6 HLA A, B, and DR identical relative who is willing and able to donate allogeneic stem cells. Serological, low resolution or mid resolution molecular typing will determine the degree of match for HLA (Human Leukocyte Antigen) class I regardless of high resolution DNA typing results. High resolution typing will be used to determine the degree of match for HLA-DR.
  • No untreated or uncontrolled invasive infections. Patients still under therapy for presumed or proven infection are eligible provided there is clear evidence (radiologic and/or culture) that the infection is well controlled. Patients under treatment for infection will be enrolled only after clearance from the Principal Investigator.
  • Not pregnant

Patient Exclusion Criteria:

  • acute leukemia
  • HIV positive patients not eligible
  • Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient
  • Pregnant

Donor Inclusion Criteria:

  • 5/6 or 6/6 HLA match for HLA-A, B, and DR
  • Age 3-70 years, good general health
  • No contraindication to G-CSF (Granulocyte Colony-Stimulating Factor)stimulation
  • No contraindication to leukapheresis of peripheral blood stem cells
  • Good general health

Donor Exclusion Criteria:

  • HIV positive or history of HIV risk factors
  • Presence of other diseases transmissible by blood that pose unacceptable risk to the study subject.
  • Pregnant
  • Medical or psychological conditions that would make the donor unlikely to tolerate G-CSF - injections or leukapheresis
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Immunosuppression Taper

    Reduced intensity conditioning consisting of Busulfan and Fludarabine(fludarabine 150 mg/m2 IV, busulfan 6 mg/kg IV, total lymphoid irradiation 2 Gy), followed by a rapid immunosuppressive taper of Tacrolimus (0.06 mg/kg q12h, PO, Days -7 to +28), Methotrexate (5 mg/m2, IV, Days +1, +3, +6, +11) and Mycophenolate Mofetil (10 mg/kg every 8 hours, PO, Days -6 to +7).

    Procedure: Reduced intensity conditioning · Procedure: Rapid immunosuppressive taper · Procedure: Prophylactic donor leukocyte infusions

Interventions

  • ProcedureReduced intensity conditioning

    Busulfan and Fludarabine regimen

  • ProcedureRapid immunosuppressive taper

    Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil

  • ProcedureProphylactic donor leukocyte infusions

    If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4

    The primary objective of this study was to establish the rate of acute GVHD following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. Glucksberg staging was used for organ grading of GVHD. Clinical GVHD was assessed as follows: Grade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 rash and no liver or gut involvement Grade 2: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 GI Grade 3: Stage 0-3 skin with Stage 2-3 liver, or Stage 2-4 GI Grade 4: Stage 4 skin rash, or Stage 4 liver involvement

    Time frame: 100 days

  2. Percentage of Participants With Progression Free Survival

    The second primary objective was to determine the percentage of participants with progression free survival following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. We define disease progression as disease recurrence within 180 days of transplant.

    Time frame: two years

Secondary outcomes

  1. Percentage of Patients Alive at 2 Years

    To estimate the overall survival of patients progression following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies.

    Time frame: 2 Years

07

Results

Posted Jun 20, 2014

Participant flow

Participant flow — Overall Study
MilestoneImmunosuppression Taper
Started54
Completed54
Not completed0

Outcome measures

PrimaryPercentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4

The primary objective of this study was to establish the rate of acute GVHD following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. Glucksberg staging was used for organ grading of GVHD. Clinical GVHD was assessed as follows: Grade 0: No stage 1-4 of any organ Grade 1: Stage 1-2 rash and no liver or gut involvement Grade 2: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 GI Grade 3: Stage 0-3 skin with Stage 2-3 liver, or Stage 2-4 GI Grade 4: Stage 4 skin rash, or Stage 4 liver involvement

Time frame:
100 days
Reported as:
Number · percentage of participants
Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4
percentage of participantsImmunosuppression Taper
Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-473
PrimaryPercentage of Participants With Progression Free Survival

The second primary objective was to determine the percentage of participants with progression free survival following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies. We define disease progression as disease recurrence within 180 days of transplant.

Time frame:
two years
Reported as:
Number · percentage of participants
Percentage of Participants With Progression Free Survival
percentage of participantsImmunosuppression Taper
Percentage of Participants With Progression Free Survival35
SecondaryPercentage of Patients Alive at 2 Years

To estimate the overall survival of patients progression following prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies.

Time frame:
2 Years
Reported as:
Number · percentage of participants
Percentage of Patients Alive at 2 Years
percentage of participantsImmunosuppression Taper
Percentage of Patients Alive at 2 Years38

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immunosuppression Taper—42/54 (77.8%)30/54 (55.6%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventImmunosuppression Taper
InfectionInfections and infestations16/54
DiarrheaGastrointestinal disorders10/54
GVHDImmune system disorders9/54
FeverGeneral disorders5/54
VomitingGastrointestinal disorders4/54
NauseaGastrointestinal disorders4/54
Abdominal painGastrointestinal disorders4/54
DeathGeneral disorders3/54
HypotensionCardiac disorders2/54
PyrexiaGeneral disorders2/54
Most frequent other events
Showing 10 of 21
Most frequent other events
EventImmunosuppression Taper
HyperglycemiaMetabolism and nutrition disorders29/54
HypocalcemiaMetabolism and nutrition disorders28/54
HypoalbuminemiaMetabolism and nutrition disorders24/54
HypomagnesemiaMetabolism and nutrition disorders23/54
HyponatremiaMetabolism and nutrition disorders20/54
ASTInvestigations20/54
ALTInvestigations20/54
CreatinineInvestigations18/54
HypokalemiaMetabolism and nutrition disorders17/54
HypermagnesemiaMetabolism and nutrition disorders16/54

Baseline characteristics

54 patients were enrolled however 9 patients did not receive planned donor lymphocyte infusion. 45 patients were analyzed.

Age, Continuous
Age, Continuous(years)Immunosuppression Taper
Median56 (2 to 67)
Gender
Gender(Participants)Immunosuppression Taper
Female22
Male23
08

Study locations

1 site
  • The University of Michigan
    Ann Arbor, Michigan 48109, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00143845
Lead sponsor
University of Michigan Rogel Cancer Center
Responsible party
Sponsor
First posted
Sep 2, 2005
Start date
Apr 2003
Primary completion
Nov 2010
Completion
Feb 2013
Results posted
Jun 20, 2014
Last update
Mar 8, 2017

Study contacts

John E. Levine, MD, MS
principal investigator · The Univeristy of Michigan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion